Computerized Registry of Patients With Venous Thromboembolism (RIETE)

Description

The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with the purpose of decreasing mortality, frequency of thromboembolic recurrences as well as bleeding complications and arterial events. As an additional objective RIETE is also aimed to create predictive scores that help physicians to better identify patients with high risk of presenting some of these complications. The primary parameters recorded by the registry comprise details of each patient's clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome (during the first 3 months of therapy) of antithrombotic treatment. Study endpoints are clinically recognized (and objectively confirmed) recurrences of VTE, major and minor bleeding complications, and death.

Conditions

Venous Thromboembolism

Study Overview

Study Details

Study overview

The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with the purpose of decreasing mortality, frequency of thromboembolic recurrences as well as bleeding complications and arterial events. As an additional objective RIETE is also aimed to create predictive scores that help physicians to better identify patients with high risk of presenting some of these complications. The primary parameters recorded by the registry comprise details of each patient's clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome (during the first 3 months of therapy) of antithrombotic treatment. Study endpoints are clinically recognized (and objectively confirmed) recurrences of VTE, major and minor bleeding complications, and death.

Computerized Registry of Patients With Venous Thromboembolism (RIETE)

Computerized Registry of Patients With Venous Thromboembolism (RIETE)

Condition
Venous Thromboembolism
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale University School of Medicine, New Haven, Connecticut, United States, 06510

Jacksonville

College of Medicine - Jacksonville University of Florida, Jacksonville, Florida, United States, 32209

Evanston

Evanston NorthShore University HealthSystem, Evanston, Illinois, United States, 60201

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Manhasset

Northwell Health System, Manhasset, New York, United States, 11021

Milwaukee

Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Confirmed VTE (acute deep-vein thrombosis, pulmonary embolism and/or superficial venous thrombosis) by objective tests.
  • * Informed consent to the participation in the study, according to the requirements of the ethics committee within each hospital.
  • * Participation in a therapeutic clinical trial with an unknown drug.
  • * Inability to the 3 month follow-up

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Manuel Monreal,

Manuel Monreal, STUDY_CHAIR, Foundation for the study of VTE diseases. (FUENTE)

Study Record Dates

2027-12